Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood|October 20, 2020
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myelomaMeletios Dimopoulos, Sara Bringhen, Pekka Anttila, et al.
Cancers|April 3, 2021
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to MelflufenJuho J Miettinen, Romika Kumari, Gunnhildur Asta Traustadottir, et al.
Annals of Hematology|November 2, 2019
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma GroupSini Luoma, Pekka Anttila, Marjaana Säily, et al.
Leukemia & Lymphoma|April 10, 2020
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaKatja Weisel, Meletios Dimopoulos, Philippe Moreau, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Cancers|March 13, 2024
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study GroupAnu Partanen, Anders Waage, Valdas Peceliunas, et al.
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Pageof 3